Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0HYRZD
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
BAY-1862864
|
|||||
| Synonyms |
BAY 1862864; BAY-1862864; BAY1862864; CD22-Thorium-conjugate; Epratuzumab Th-227 conjugate; epratuzumab-227Th-conjugate; epratuzumab-Th227-conjugate
Click to Show/Hide
|
|||||
| Organization |
Bayer AG
|
|||||
| Drug Status |
Phase 1 (Terminated)
|
|||||
| Indication |
In total 1 Indication(s)
|
|||||
| Drug-to-Antibody Ratio |
Undisclosed
|
|||||
| Antibody Name |
Epratuzumab
|
Antibody Info | ||||
| Antigen Name |
B-cell receptor CD22 (CD22)
|
Antigen Info | ||||
| Payload Name |
227Th
|
Payload Info | ||||
| Therapeutic Target |
Unclear
|
|||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Undisclosed
|
|||||
